Kymata Health CBD Guide
THCV (Tetrahydrocannabivarin)
A THC relative marketed for appetite and blood sugar. A 2016 pilot in type 2 diabetes saw lower fasting glucose at 5 mg twice daily. It is the cannabinoid here most exposed to the December 11, 2026 rules.
Level of human evidence: Small RCTs. Numbers in brackets link to the sources at the end of the page.
What it is
THCV is structurally close to THC. At low doses it blocks CB1 receptors; at high doses it may activate them.
How it works
Neutral antagonist at CB1 at low doses and partial agonist at CB2, based mainly on lab studies.
Human studies
In a 13-week pilot trial of 62 people with type 2 diabetes, 5 mg THCV twice daily lowered fasting glucose and improved a measure of insulin-producing cell function versus placebo. CBD alone did not.[1]
In 10 healthy men, 10 mg THCV daily for 5 days blunted some effects of THC (heart rate, memory recall) and amplified others.[2]
Doses used in studies
Studied doses: 5 mg twice daily (13 weeks) and 10 mg daily (5 days).[1][2]
Drug interactions
Not well studied. Ask a clinician before combining with diabetes medicines, since the trial measured glucose changes.[1]
Safety
Well tolerated in the small trials above; long-term safety unknown.[1][2]
Legal status
THCV is a tetrahydrocannabinol. Under the new definition, products with THC-like cannabinoids above 0.4 mg per container stop counting as hemp on December 11, 2026, so most THCV products are likely to be affected.[3]
From December 11, 2026, federal law counts a finished hemp product as hemp only if the whole container holds no more than 0.4 mg of total THC (including THCA and THC-like cannabinoids). Full-spectrum products usually hold far more than that per bottle, so THC-free (isolate or verified broad-spectrum) products are the safe choice. State rules differ and can be stricter.[3]
Other cannabinoids
Compare brands on lab data: best CBD oils, ranked.
Sources
- Jadoon KA et al. Efficacy and safety of CBD and THCV on glycemic and lipid parameters in type 2 diabetes: RCT. Diabetes Care 2016
- Englund A et al. Five-day dosing with THCV on THC-induced effects in healthy men: crossover pilot. J Psychopharmacol 2016
- Congressional Research Service: Changes to the statutory definition of hemp (IF13136)